Risultati della ricerca - Hui‐Ling Zhen

  • Mostra 1 - 12 risultati su 12
Raffina i risultati
  1. 1
    Clinicogenomic Analysis of <i>FGFR2</i>-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib

    Clinicogenomic Analysis of <i>FGFR2</i>-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib di Ian M. Silverman, Antoine Hollebecque, Luc Friboulet, Sherry Owens, Robert Newton, Hui‐Ling Zhen, Luis Féliz, Camilla Zecchetto, Davide Melisi, Timothy C. Burn

    Pubblicazione 2020
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  2. 2
    Interim results of fight-201, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC) harboring fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations (GA)

    Interim results of fight-201, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC) harbori... di Andrea Necchi, Damien Pouessel, Raya Leibowitz‐Amit, Aude Fléchon, Sumati Gupta, Philippe Barthélémy, Michele Maio, Xinhua Zhu, Ekatherine Asatiani, Gul Serbest, Hui‐Ling Zhen, Yohann Loriot

    Pubblicazione 2018
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  3. 3
    A Phase 2 Study of Pemigatinib (FIGHT-203; INCB054828) in Patients with Myeloid/Lymphoid Neoplasms (MLNs) with Fibroblast Growth Factor Receptor 1 (FGFR1) Rearrangement (MLN <i>FGFR1</i>)

    A Phase 2 Study of Pemigatinib (FIGHT-203; INCB054828) in Patients with Myeloid/Lymphoid Neoplasms (MLNs) with Fibroblast Growth Factor Receptor 1 (FGFR1) Rearrangement (MLN <i>FGF... di Jason Gotlib, Jean‐Jacques Kiladjian, Alessandro M. Vannucchi, Alessandro Rambaldi, Andreas Reiter, William Shomali, Tracy I. George, Jay Patel, Philomena Colucci, Chris Walker, Hui‐Ling Zhen, Srđan Verstovšek

    Pubblicazione 2021
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  4. 4
    Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results

    Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results di Srđan Verstovšek, Francesco Passamonti, Alessandro Rambaldi, Giovanni Barosi, Elisa Rumi, Elisabetta Gattoni, Lisa Pieri, Hui‐Ling Zhen, Muriel Granier, Albert Assad, Mario Cazzola, Hagop M. Kantarjian, Tiziano Barbui, Alessandro M. Vannucchi

    Pubblicazione 2017
    Testo Testo
    Carta
    Aggiungi alla lista
    Salvato in:
  5. 5
    Changes in quality of life and disease‐related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy

    Changes in quality of life and disease‐related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy di Ruben A. Mesa, Srđan Verstovšek, Jean‐Jacques Kiladjian, Martin Grießhammer, Tamás Masszi, Simon Durrant, Francesco Passamonti, Claire Harrison, Fabrizio Pane, Pierre Zachée, Hui‐Ling Zhen, Mark M. Jones, Shreekant Parasuraman, Jingjin Li, Isabelle Côté, Dany Habr, Alessandro M. Vannucchi

    Pubblicazione 2015
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  6. 6
    The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double‐blind, double‐dummy, symptom study (RELIEF)

    The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double‐blind, double‐dummy, symptom... di Ruben A. Mesa, Alessandro M. Vannucchi, Abdulraheem Yacoub, Pierre Zachée, Mamta Garg, Roger M. Lyons, Steffen Koschmieder, Ciro R. Rinaldi, Jenny Byrne, Yasmin Hasan, Francesco Passamonti, Srđan Verstovšek, Deborah Hunter, Mark M. Jones, Hui‐Ling Zhen, Dany Habr, Bruno Martino

    Pubblicazione 2016
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  7. 7
    FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with <i>FGFR2</i> rearrangements

    FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with <i>FGFR2</i> rearrangements di Tanios Bekaii‐Saab, Juan W. Valle, Eric Van Cutsem, Lorenza Rimassa, Junji Furuse, Tatsuya Ioka, Davide Melisi, Teresa Macarulla, John Bridgewater, Harpreet Wasan, Mitesh J. Borad, Ghassan K. Abou‐Alfa, Ping Jiang, Christine Lihou, Hui‐Ling Zhen, Ekaterine Asatiani, Luis Féliz, Arndt Vogel

    Pubblicazione 2020
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  8. 8
    An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202

    An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202 di Arndt Vogel, Vaibhav Sahai, Antoine Hollebecque, Gina M. Vaccaro, Davide Melisi, Raed MAl Rajabi, Andrew Scott Paulson, Mitesh J. Borad, David Gallinson, Adrian Murphy, Do‐Youn Oh, Efrat Dotan, Daniel V.T. Catenacci, E. Van Cutsem, Christine Lihou, Hui‐Ling Zhen, M L Veronese, G.K. Abou-Alfa

    Pubblicazione 2024
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  9. 9
    FIGHT-202: A phase II study of pemigatinib in patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA)

    FIGHT-202: A phase II study of pemigatinib in patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA) di Arndt Vogel, Vaibhav Sahai, Antoine Hollebecque, Gina M. Vaccaro, Davide Melisi, Raed Moh’d Taiseer Al-Rajabi, Andrew Scott Paulson, Mitesh J. Borad, David Gallinson, Adrian Murphy, Do‐Youn Oh, Efrat Dotan, Daniel V.T. Catenacci, Eric Van Cutsem, Christine Lihou, Hui‐Ling Zhen, Luis Féliz, Ghassan K. Abou‐Alfa

    Pubblicazione 2019
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  10. 10
    Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

    Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study di Ghassan K. Abou‐Alfa, Vaibhav Sahai, Antoine Hollebecque, Gina M. Vaccaro, Davide Melisi, Raed Moh’d Taiseer Al-Rajabi, Andrew Scott Paulson, Mitesh J. Borad, David Gallinson, Adrian Murphy, Do‐Youn Oh, Efrat Dotan, Daniel V.T. Catenacci, Eric Van Cutsem, Tao Ji, Christine Lihou, Hui‐Ling Zhen, Luis Féliz, Arndt Vogel

    Pubblicazione 2020
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  11. 11
    Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial

    Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial di Srđan Verstovšek, A. M. Vannucchi, Martin Grießhammer, Tamás Masszi, Simon Durrant, Francesco Passamonti, C. N. Harrison, Fabrizio Pane, Pierre Zachée, Keita Kirito, Carlos Besses, Masayuki Hino, Beatriz Moiraghi, Carole B. Miller, M. Cazzola, Vittorio Rosti, I. Blau, Ruben A. Mesa, Mark M. Jones, Hui‐Ling Zhen, Li J, Nathalie Francillard, Dany Habr, Jean‐Jacques Kiladjian

    Pubblicazione 2016
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  12. 12
    Truncated FGFR2 is a clinically actionable oncogene in multiple cancers

    Truncated FGFR2 is a clinically actionable oncogene in multiple cancers di Daniel Zingg, Jinhyuk Bhin, Julia Yemelyanenko, Sjors M. Kas, Frank Rolfs, Catrin Lutz, Jessica Lee, Sjoerd Klarenbeek, Ian M. Silverman, Stefano Annunziato, Chang S. Chan, Sander R. Piersma, Timo Eijkman, Madelon Badoux, Ewa Gogola, Bjørn Siteur, Justin Sprengers, Bim de Klein, Richard R. de Goeij‐de Haas, Gregory Riedlinger, Hua Zhu Ke, Russell W. Madison, Anne Paulien Drenth, Eline van der Burg, Eva Schut, Linda Henneman, Martine H. van Miltenburg, Natalie Proost, Hui‐Ling Zhen, Ellen Wientjens, Roebi de Bruijn, Julian R. de Ruiter, Ute Boon, Renske de Korte‐Grimmerink, Bastiaan van Gerwen, Luis Féliz, Ghassan K. Abou‐Alfa, Jeffrey S. Ross, Marieke van de Ven, Sven Rottenberg, Edwin Cuppen, Anne Vaslin Chessex, Siraj M. Ali, Timothy C. Burn, Connie R. Jiménez, Shridar Ganesan, Lodewyk F.A. Wessels, Jos Jonkers

    Pubblicazione 2022
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:

Strumenti per la ricerca: